A new pancreatic cancer drug has delivered promising results in early clinical trials, raising hopes of a major advance against one of the deadliest cancers.
Daraxonrasib, a daily pill used alongside chemotherapy, helped shrink tumours in patients with advanced pancreatic cancer. In some cases, the cancer became undetectable on scans.
The phase I/II trial involved 61 patients whose pancreatic cancer had spread to other parts of the body. Researchers reported that tumours stopped growing in 90% of participants.
More than 60% experienced tumour shrinkage, while around 8% saw their cancer become undetectable on CT scans.
Cancer Research UK described the findings as a major step forward. Its Dr Sam Godfrey said the results were incredibly exciting, adding that researchers were finally making progress against a cancer that had remained difficult to treat.
Daraxonrasib works by targeting specific KRAS mutations that drive cancer growth. These mutations are common in pancreatic cancer and have historically been difficult to target with drugs.
Researchers say the treatment could also have potential applications in other cancers linked to similar mutations, including lung and ovarian cancers.
Dr Wungki Park of Memorial Sloan Kettering Cancer Center said the trial was showing higher tumour response rates, deeper responses and longer periods of disease control.
The study followed patients for an average of 18 months. However, researchers say further trials are needed to determine whether the treatment can improve long-term survival and how long its effects last.
Doctors have cautioned that the findings do not represent a cure. Even when scans show no detectable cancer, the disease may return, requiring longer follow-up studies.
Pancreatic cancer remains one of the hardest cancers to treat, with the lowest survival rate among common cancers in the UK. It causes approximately 11,500 diagnoses and 10,200 deaths annually.
Researchers say the early results offer renewed hope for patients, although further evidence will be needed to establish the treatment’s long-term benefits.


